762 Participants Needed

Pegozafermin for Liver Cirrhosis

Recruiting at 202 trial locations
Ec
Overseen ByENLIGHTEN clinical trial
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH \[previously known as nonalcoholic steatohepatitis, NASH\]).

Will I have to stop taking my current medications?

The trial protocol does not specify if you need to stop taking your current medications. However, if you are taking vitamin E at more than 400 IU per day, you must have been on a stable dose for at least 6 months before joining the trial.

Research Team

MM

Maya Margalit, MD

Principal Investigator

89bio, Inc.

Eligibility Criteria

Adults aged 18-75 with compensated cirrhosis due to MASH, confirmed by a liver biopsy showing stage F4 fibrosis. Participants must have a BMI of ≥25 (≥23 for Asians) and <50 kg/m² and at least one metabolic risk factor. Pregnant individuals or those not meeting the specific criteria are excluded.

Inclusion Criteria

I have severe liver scarring confirmed by a biopsy.
Body mass index (BMI) at screening ≥25.0 (≥23.0 for Asian participants) and <50.0 kg/m^2
At least 1 metabolic risk factor
See 1 more

Exclusion Criteria

My liver condition is not MASH.
My liver is not working properly.
I have or had liver cancer.
See 3 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive pegozafermin or placebo for the duration of the study

24 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Pegozafermin
Trial Overview The trial is testing Pegozafermin's effectiveness and safety against a placebo in treating compensated cirrhosis caused by MASH. It involves administering Pegozafermin to see if it improves liver health compared to no active treatment.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: PegozaferminExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Matched placebo

Find a Clinic Near You

Who Is Running the Clinical Trial?

89bio, Inc.

Lead Sponsor

Trials
7
Recruited
2,600+